# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-26T15:23:24.103940
**Route:** OpenRouter + LaTeX
**Paper Hash:** 7b9ad4e975b3c7b7
**Tokens:** 15906 in / 1233 out
**Response SHA256:** 4ad0620d559107ef

---

No fatal errors detected in the four critical categories you specified.

### 1) DATA–DESIGN ALIGNMENT (CRITICAL)
- **Treatment timing vs. data coverage:** Treatment is defined as exposure beginning in **2014** (Post2014), and the panel is stated to cover **2005–2023**. This provides both pre- and post-treatment periods. No timing impossibility detected.
- **Post-treatment observations:** There are post-2014 observations (2014–2023) for the whole panel, so the DiD design has post-treatment support.
- **Treatment definition consistency:** The treatment is consistently defined throughout as \(\overline{OilRents}_{2010-2013} \times \mathbf{1}[t \ge 2014]\). The same construct appears in the main regressions, event study, and mechanism regressions. No mismatches found.

### 2) REGRESSION SANITY (CRITICAL)
I scanned the reported regression outputs in:
- Table 2 (Main results), Table 3 (Alternative outcomes), Table 4 (Robustness checks), Table 5 (Mechanism), Table 6 (Region-specific)

Checks:
- **SE magnitude:** All SEs are in plausible ranges (no explosive/collinearity-looking SEs like thousands; no cases where SE > 100×|coef|).
- **Coefficient magnitude:** All coefficients are plausible for the units described (mortality per 1,000; spending shares of GDP; immunization rates).
- **Impossible values:** No R² shown (not required by your criteria). No NA/NaN/Inf/negative SE values appear.

### 3) COMPLETENESS (CRITICAL)
- Regression tables report **standard errors** and **sample sizes (N / Observations)** where applicable.
- No “TBD/TODO/XXX/NA” placeholders appear in tables/results.
- Methods described (main DiD, event study, placebo, mechanism) have corresponding results shown (tables/figures are referenced and included as LaTeX figure environments; I cannot verify the external PDF files exist, but there is no *internal* placeholder/omission in the source).

### 4) INTERNAL CONSISTENCY (CRITICAL)
- The preferred estimate in the abstract (0.035; CI \([-0.156, 0.227]\)) matches **Table 2, column (2)** exactly.
- Sample sizes are consistent where they should be (preferred specification uses 2,506 in Table 2 col (2); same “Baseline (preferred)” row in robustness table reports 2,506).
- Treatment timing (2014 cutoff) is used consistently across main design, event study, placebo timing discussion, and narrative.

ADVISOR VERDICT: PASS